US05337M1045
© Globe Newswire
05.12.2025
AVDL
LISTED
NASDAQ
Announcement relating to despatch of Rule 15 proposal
News Preview
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION....
Themefolio
Profiler
Peergroup
© Globe Newswire
03.12.2025
AVDL
LISTED
NASDAQ
Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General Meeting
News Preview
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION....
Themefolio
Profiler
Peergroup
© Globe Newswire
01.12.2025
AVDL
LISTED
NASDAQ
Announcement relating to convening of Scheme Meeting and Extraordinary General Meeting
News Preview
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION....
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
17.11.2025
AVDL
LISTED
NASDAQ
Avadel Board of Directors Declares Lundbeck Proposal a “Company Superior Proposal”
News Preview
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
14.11.2025
AVDL
LISTED
NASDAQ
Avadel Receives Unsolicited Proposal from Lundbeck
News Preview
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014...
Themefolio
Profiler
Peergroup
© BusinessWire
22.10.2025
AVDL
LISTED
NASDAQ
Avadel Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avadel Pharmaceuticals plc - AVDL
News Preview
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Avadel Pharmaceuticals plc (NasdaqGM: AVDL) to Alkermes plc (NasdaqGS: ALKS). Under the terms of the proposed transaction, shareholders of Avadel will receive $18.50 per share, plus a non-tra...
Themefolio
Profiler
Peergroup
© BusinessWire
22.10.2025
AVDL
LISTED
NASDAQ
AVDL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avadel Pharmaceuticals plc Is Fair to Shareholders
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avadel Pharmaceuticals plc (NASDAQ: AVDL) to Alkermes plc is fair to Avadel shareholders. Under the terms of the proposed transaction, Avadel shareholders will receive $18.50 per share, plus a non-transferable contingent value right entitling holders to a potential...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.10.2025
AVDL
LISTED
NASDAQ
Avadel Pharmaceuticals and Jazz Pharmaceuticals Reach Global Settlement
News Preview
DUBLIN, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the global settlement of all litigation with Jazz Pharmaceuticals Inc. (“Jazz”)....
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
AVDL
LISTED
NASDAQ
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
News Preview
DUBLIN, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to seven (7) new employees to purchase 161,600 ordinary shares under Avadel’...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2025
AVDL
LISTED
NASDAQ
Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research Funding
News Preview
A Media Snippet accompanying this announcement is available by clicking on this link....
Themefolio
Profiler
Peergroup
© Globe Newswire
10.09.2025
AVDL
LISTED
NASDAQ
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
News Preview
DUBLIN, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to five (5) new employees to purchase 165,520 ordinary shares under Avadel’...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.09.2025
AVDL
LISTED
NASDAQ
Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension at World Sleep 2025
News Preview
– 17 abstracts accepted, including one oral presentation –...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
03.09.2025
AVDL
LISTED
NASDAQ
Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd
News Preview
– Expands Avadel’s pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia –...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.08.2025
AVDL
LISTED
NASDAQ
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
News Preview
DUBLIN, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.08.2025
AVDL
LISTED
NASDAQ
Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance
News Preview
-- Generated LUMRYZ™ net revenue of $68.1 million, a 64% increase compared to second quarter 2024, net income of $9.7 million and earnings per share of $0.10 -- -- 3,100 patients on LUMRYZ as of June 30, 2025, a 63% increase compared to June 30, 2024 --...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.06.2025
AVDL
LISTED
NASDAQ
Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation
News Preview
DUBLIN, June 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that, on Friday, June 27, 2025, the U.S. Court of Appeals for the District of Columbia Circuit (the “Appeals Court”) affirmed a prior decision of the U.S. District Court f...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.06.2025
AVDL
LISTED
NASDAQ
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
News Preview
DUBLIN, June 16, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to two new employees to purchase 9,600 ordinary shares under Avadel’s 2021 I...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.05.2025
AVDL
LISTED
NASDAQ
Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer
News Preview
DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- DUBLIN, May 13, 2025 – Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the appointment of Susan Rodriguez as Chief Operating Officer. In this newly created role, Ms. Rodriguez will lead all aspects of the Company's...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.05.2025
AVDL
LISTED
NASDAQ
Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance
News Preview
-- Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 and a 100% year over year increase over the first quarter of 2024 --...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.05.2025
AVDL
LISTED
NASDAQ
Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction
News Preview
- With this ruling, Avadel can seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia -...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.04.2025
AVDL
LISTED
NASDAQ
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
News Preview
DUBLIN, April 10, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to nine (9) new employees to purchase 48,400 ordinary shares under Avadel’s...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.04.2025
AVDL
LISTED
NASDAQ
Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference
News Preview
DUBLIN, April 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today presented at the 24th Annual Needham Virtual Healthcare Conference....
Themefolio
Profiler
Peergroup
© Globe Newswire
01.04.2025
AVDL
LISTED
NASDAQ
Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference
News Preview
DUBLIN, April 01, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference on Tuesday, April 8 at 1:30 p.m. ET....
Themefolio
Profiler
Peergroup
© Globe Newswire
03.03.2025
AVDL
LISTED
NASDAQ
Avadel Pharmaceuticals Reiterates 2025 Guidance as it Reports Fourth Quarter and Full Year 2024 Financial Results
News Preview
-- LUMRYZ™ generated $50.4 million in sales in the fourth quarter, up 158% year-over-year, taking the full-year total to $169.1 million, in line with preliminary results published January 8...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.02.2025
AVDL
LISTED
NASDAQ
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3
News Preview
DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, March 3, 2025, to provide a corporate update and discuss the Company's financial resu...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.01.2025
AVDL
LISTED
NASDAQ
Avadel Pharmaceuticals Appoints Sev Melkonian as Vice President of Patient Services, Distribution, and Reimbursement
News Preview
DUBLIN, Ireland, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that Sev Melkonian has joined the company as Vice President of Patient Services, Distribution, and Reimbursement. Mr. Melkonian has extensive industry exper...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.01.2025
AVDL
LISTED
NASDAQ
Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch
News Preview
-- Approximately $50.0 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 patients on LUMRYZ as of December 31, 2024, including 600 patients that initiated therapy in the fourth quarter --...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.01.2025
AVDL
LISTED
NASDAQ
Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8
News Preview
DUBLIN, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, January 8, 2025, to provide a corporate update and discuss the Company's prelimina...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2024
AVDL
LISTED
NASDAQ
Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference
News Preview
DUBLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20 at 7:30 a.m. GMT / 2:30 a.m. E...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2024
AVDL
LISTED
NASDAQ
Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial Results
News Preview
-- Generated $50.0 million in net revenue from sales of LUMRYZ™ -- --2,300 patients on LUMRYZ as of September 30th, including 700 patients that initiated therapy in the quarter --...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.10.2024
AVDL
LISTED
NASDAQ
Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation
News Preview
DUBLIN, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that yesterday, the U.S. District Court for the District of Columbia (“Court”) ruled in favor of the Food and Drug Administration (“FDA”) in a suit brought by Jazz Pharmac...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.10.2024
AVDL
LISTED
NASDAQ
Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy
News Preview
-- LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy—...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.08.2024
AVDL
LISTED
NASDAQ
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
News Preview
DUBLIN, Ireland, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.06.2024
AVDL
LISTED
NASDAQ
Avadel Pharmaceuticals to Join Russell 3000® Index
News Preview
DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equit...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.05.2024
AVDL
LISTED
NASDAQ
Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024
News Preview
– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ –...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.05.2024
AVDL
LISTED
NASDAQ
Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results
News Preview
-- Generated $27.2 million in net revenue from sales of LUMRYZ™ -- -- Through March 31, greater than 2,800 patients enrolled in Avadel’s RYZUP patient support services and more than 1,700 patients initiated therapy --...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.05.2024
AVDL
LISTED
NASDAQ
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8
News Preview
DUBLIN, Ireland, May 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 8, 2024, to provide a corporate update and discuss the Company's finan...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
